Multi-institutional observational study for the efficacy and safety of Carfilzomib for multiple myeloma in Kyoto Clinical Hematology Study Group (KOTOSG)

Multi-institutional observational study for the efficacy and safety of Carfilzomib for multiple myeloma in Kyoto Clinical Hematology Study Group (KOTOSG) - KOTOSG-CFZ observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025108

Enrollment

Registered

2016-12-01

Start date

2017-06-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients between 20 and 99 years old who received Carfilzomib-containing therapy

Exclusion criteria

Exclusion criteria: Patients who reject the enrollment in the study.

Design outcomes

Primary

Measure	Time frame
Efficacy of Carfilzomib-containing therapy for multiple myeloma	—

Countries

Japan

Contacts

Public ContactJUNYA KURODA

Kyoto Prefectural University of Medicine Division of Hamatology and Oncology

junkuro@koto.kpu-m.ac.jp075-251-5740

Outcome results